Anti-VEGF for AMD a top advancement

February 28, 2010

San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

San Francisco-Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

The treatment received the highest percentage of votes from the 423 survey participants.

Other noted advancements and the percentages of survey respondents who voted for them:

• Optical coherence tomography (24%).

• Prostamide (prostaglandin-ethanolamide) eye drops for glaucoma (6.6%).

• Premium IOLs, the femtosecond laser, gene therapy for Leber's congenital amaurosis, and Descemet's stripping automated endothelial keratoplasty (about 3% each).